作为营收支柱的硬脑膜补片业务，正面临多重压力。集采政策冲击下的价格体系松动、国产竞品的技术 追赶，叠加自身产品迭代缓慢，共同构成了增长瓶颈。单一产品依赖的商业模式，在市场竞争加剧的背 景下更显脆弱。 研发投入的持续收缩与技术转化的低效，使得第二增长曲线迟迟未现。人工肝、CAR-T等前沿布局与核 心业务缺乏协同，而核心产品创新"断档"的隐患，正让公司在行业变革中逐渐失去主动权，未来发展的 不确定性进一步放大。 业绩增长的背后 本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 冠昊生物的半年报数据看似显现出回暖迹象，营收与利润的双增长为这家曾被视为"再生医学明星"的企 业带来短暂的市场关注。但拉长周期观察，核心业务的增长停滞与结构性矛盾已逐渐显现。这家曾以再 生医学技术为标签的企业，正陷入"短期数据回暖"与"长期发展乏力"的张力之中。 2025年半年报显示，公司营收2.01亿元，同比微增5.89%；归母净利润2040万元，增速仅1.27%。 若将时间轴拉长至五年，这份"平淡无奇"的中报，不过是公司漫长估值消化周期的最新注脚。 Wind数据显示，2020—2024年，公司营收从4.37亿元降至3 ...

Core Viewpoint - The establishment of the Xiamen University-Guyu Biomedicine Joint Research Center and the launch of the human-like exosome HME represent a significant breakthrough in the application of exosomes in the beauty industry, potentially overcoming the challenges of industrialization and safety [3][4][5]. Group 1: Understanding Exosomes - Exosomes are small vesicles that facilitate intercellular communication by delivering proteins and nucleic acids, playing a crucial role in regulating metabolism and cellular repair [5][6]. - The decline in the function of exosomes with aging highlights their importance in anti-aging treatments, as they are essential for maintaining healthy cellular communication [6][8]. Group 2: Challenges in Application - Current market offerings primarily feature plant-derived exosomes, which are less effective due to structural differences with human cells, while human-derived exosomes face regulatory challenges and safety concerns [8][10]. - The classification of exosomes as Advanced Therapy Medicinal Products (ATMP) by the Chinese National Medical Products Administration indicates a clearer direction for research and application in the industry [8][10]. Group 3: Breakthrough of HME - The human-like exosome HME is not a simple extraction from natural exosomes but a product of reverse engineering and optimization, addressing safety, efficiency, and industrialization challenges [10][12]. - HME mimics the structure and active components of human-derived exosomes, allowing for better cellular recognition and uptake, thus enhancing delivery efficiency [12][13]. Group 4: Advantages of HME - HME directly regulates target genes and signaling pathways, significantly shortening the action mechanism compared to traditional anti-aging ingredients [16]. - The incorporation of targeting peptides in HME allows for precise delivery to key skin cells responsible for regeneration, improving utilization compared to conventional treatments [16][17]. - HME can be stored at room temperature, overcoming the stability issues associated with natural exosomes, thus facilitating large-scale production [17][18]. Group 5: Research and Development Strategy - The collaboration with Xiamen University enhances Guyu's research capabilities, shifting focus from application optimization to foundational research in anti-aging [22][23]. - The development of rare ginsenoside CK for anti-aging drug research reflects a strategic move to strengthen the brand's capabilities in raw material selection and efficacy validation [23][24]. Group 6: Future Directions - The introduction of HME signifies a transition towards gene-level research in skincare, aiming to directly influence cellular functions and reverse aging processes [25][26]. - Guyu's approach aligns with the broader goals of life sciences, positioning the brand uniquely in the competitive landscape of global beauty technology [25][26].

Industry Overview - The exosome industry in China is experiencing strong growth, with a market size projected to reach 2.279 billion yuan in 2024, representing a year-on-year increase of 22.72% [1][7]. - Exosomes are membrane vesicles released from cells that play a crucial role in intercellular communication, containing various biomolecules such as proteins, lipids, and nucleic acids [2][6]. Industry Chain - The upstream of the exosome industry includes sources like animal, plant, and microbial exosomes, along with necessary biological reagents and production equipment [6]. - The midstream focuses on the production and manufacturing of exosomes, while the downstream applications span medical, aesthetic, and research services [6]. Key Applications - In the medical field, exosomes are utilized for tumor treatment by modulating the tumor microenvironment and delivering drugs [7]. - Exosomes serve as ideal biomarkers for liquid biopsies due to their high stability, enabling dynamic monitoring of tumor progression [7]. - In the aesthetic sector, exosomes are leveraged for anti-aging products due to their active components and low immunogenicity [7]. Market Size - The continuous advancement in biotechnology and exploration of intercellular communication mechanisms have led to significant developments in emerging technologies like engineered exosomes and microfluidics [1][11]. - The exosome market in China is projected to grow significantly, with a market size of 2.279 billion yuan expected in 2024, reflecting a 22.72% increase from the previous year [1][11]. Key Companies - Beijing Enze Kangtai Biotechnology Co., Ltd. has established a leading position in the engineered exosome sector with its GMP production facility and extensive collaborations [8]. - Guodian (Beijing) Pharmaceutical Technology Co., Ltd. focuses on innovative drug development using iPS cells and exosomes, particularly for neurological and immune-related diseases [9]. Industry Development Trends - Technological innovations are expected to enhance the efficiency and precision of exosome extraction, purification, and detection, facilitating large-scale production [11]. - The application of exosomes in disease diagnosis and treatment is anticipated to expand, with specific biomarkers being utilized for early diagnosis and therapeutic delivery [12]. - Increased government support and the establishment of industry standards will lead to stricter quality control and production practices in the exosome sector [13].

Group 1: Gold Market Insights - Despite a slight strengthening of the dollar, the mainstream market expectation is that the Federal Reserve will initiate a rate cut cycle by 2025, supported by recent moderate inflation data, which is a core driver for gold prices [1] - As the interest rate hike cycle approaches its end, the trend of declining real interest rates is clear, reducing the opportunity cost of holding gold as a non-yielding asset, thus solidifying the mid-term bullish outlook [1] - The expansion of the U.S. fiscal deficit raises concerns about the sustainability of U.S. debt, coupled with the Biden administration's tough stance on international trade, leading to systemic doubts among investors regarding the dollar and U.S. assets [1] Group 2: Brain-Computer Interface Market - Hubei Province has included invasive brain-computer interface surgeries in medical insurance, priced at 6,552 yuan (approximately 936 USD), significantly lower than Neuralink's cost of 50,000 USD, highlighting a competitive advantage [1] - The price difference reflects not only lower manufacturing and surgical costs but also China's systematic support for brain-computer interface technology in medical policies, which is expected to stimulate large-scale market demand, particularly in rehabilitation, elderly care, and treatment of neurological diseases [1] - Advanced flexible electrode technology, significantly smaller than a human hair, enables paralyzed patients to control games with their minds, while Brain Tiger Technology's "North Brain No. 1" allows epilepsy patients to operate WeChat and Taobao through brain control, showcasing technological advancements comparable to Neuralink [1] Group 3: Collagen Market Dynamics - The controversy surrounding Giant Bio's "Kefumei" product's collagen content is fundamentally a market competition between two technological routes: hyaluronic acid vs. recombinant collagen [1] - Huaxi Bio's active involvement and direct questioning of the capital market's excessive hype around the "recombinant collagen" concept indicate its defensive posture amid profit declines and industry shifts [1] - According to Frost & Sullivan, the overall collagen market is projected to reach 173.8 billion yuan by 2027, significantly surpassing the current scale of the hyaluronic acid industry, with a compound annual growth rate exceeding 50% [1] Group 4: Dairy Industry Challenges - Bright Dairy is facing a structural downturn in the industry characterized by weak consumer demand and intensified price wars, coupled with conservative internal business strategies, leading to a decline from being the "first stock in dairy" to a marginal competitor [3] - Although it maintains a leading position in the low-temperature milk sector, its market share is being closely approached by Yili and Mengniu, with emerging brands continuously eroding its market share [3] - For investors, this indicates that Bright Dairy currently lacks a stable competitive moat and core growth drivers, and without structural transformation, its long-term value will continue to be eroded [3] Group 5: Hair Care Market Trends - The hair care market is expected to grow from 22 billion yuan in 2025 to 50 billion yuan by 2030, with a compound annual growth rate of 15.3%, significantly outpacing the overall personal care industry [5] - The user base is projected to exceed 300 million, with young people, women, and postpartum groups being the main driving forces, as consumption scenarios expand from simple hair loss prevention to "daily care + precise repair + digital experience" [5] - AI scalp detection and genetic screening are creating personalized solutions, significantly improving user retention rates, with repurchase rates reaching over 45% [5]